Allergic Rhinitis - Epidemiology Forecast - 2034

Key Highlights

• Allergic rhinitis may be incorrectly diagnosed because its symptoms closely resemble those of other nasal disorders. The complexity of the condition and the overlap of symptoms with other nasal ailments can lead to patients experiencing misdiagnosis.
• The analyst projects that the Prevalent Cases of Allergic Rhinitis in 7MM were approximately 177.9 million in 2022 and these cases are going to increase owing to environmental factors, genetics, and lifestyle changes.
• In 2022, as per the assessment, ~88.5 million Diagnosed Prevalent Cases of Allergic Rhinitis were estimated in the 7MM. These cases are anticipated to rise by 2034 at a significant CAGR.
• In 2022, the total number of Diagnosed Prevalent Cases of Allergic Rhinitis was approximately 38 million in EU4 and the UK, which is anticipated to increase during the study period [2020-2034].
• Among the European countries, Germany had the highest diagnosed prevalent population of allergic rhinitis, followed by the UK and France.
• According to estimates, Japan accounted for the highest proportion (nearly 29%) of the total number of Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM in 2022.

The “Allergic Rhinitis - Epidemiology - 2034” report delivers an in-depth understanding of Allergic Rhinitis, historical and forecasted epidemiology of Allergic Rhinitis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Allergic Rhinitis Disease Understanding

Allergic Rhinitis Overview

Allergic rhinitis manifests as an atopic ailment characterized by symptoms such as sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It involves an IgE-mediated immune response to inhaled antigens in the immediate phase, followed by a leukotriene-mediated late phase.

The pathophysiology of allergic rhinitis involves a complex interplay of immune responses, including the participation of antigen-presenting cells, T lymphocytes, and B lymphocytes. Allergic sensitization depends on environmental allergen exposure and results in the generation of allergen-specific IgE that circulates in the peripheral blood and attaches itself to mast cells and basophils. Subsequent nasal exposure to allergen activates these cells, leading to the release of mediators that produce acute nasal symptoms.

Allergic Rhinitis Diagnosis

Allergic rhinitis is diagnosed through a detailed history, physical examination checking for nasal swelling and secretions, and assessing signs like allergic shiners. Diagnostic tests like skin prick tests or allergen-specific IgE tests confirm allergies. Skin prick tests involve introducing allergens to the skin, while IgE tests measure allergy-related substances in the blood.

The challenges associated with the diagnosis of allergic rhinitis include the need for a thorough history and physical examination to establish the clinical diagnosis, followed by further diagnostic testing to confirm that underlying allergies cause the rhinitis. Skin prick testing is the primary method for identifying specific allergic triggers of rhinitis, but local allergic rhinitis is a differentiated rhinitis phenotype that can only be recognized if additional tests are performed.

Allergic Rhinitis Epidemiology

For the purpose of designing the patient-based model for Fuchs Endothelial Corneal Dystrophy (FECD), the report provides historical as well as forecasted epidemiology segmented by Prevalent cases of Allergic Rhinitis, Diagnosed Prevalent Cases of Allergic Rhinitis, Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis, Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis, and Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• According to estimations, approximately 177.9 million Prevalent Cases of Allergic Rhinitis were found in 2022 in the 7MM.
• In 2022, the Diagnosed Prevalent Cases of Allergic Rhinitis amounted to ~88.5 million across the 7MM, with Japan leading in terms of diagnosed prevalent population share, followed by the United States. These cases are expected to increase during the study period (2020-2034).
• According to estimates, the Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK were found to be 38 million in 2022. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of Allergic Rhinitis cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.
• As per the analysis, the Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis based on age were categorized into 0-10 years, 10-17 years, 18-59 years, 60 years and above. The highest number of cases (~14.8 million) was accounted for by the 18-59 years age group in 2022 in the US.
• The Severity-specific Diagnosed Prevalent Cases Of Allergic Rhinitis were divided into mild, moderate, and severe. In 2022, the moderate category accouted for the highest number of cases among the EU4 and the UK.
• The Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis were categorized into grass pollen, mites, tree pollen, animal dander, fungal spores, and weed pollen. In the 7MM, grass pollen accounted for the highest number of allergic rhinitis cases, comprising nearly 50.5 million cases.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Division of Allergy and Immunology at the University of California in Irvine, Division of Allergy, Immunology, and Rheumatology, Georgetown University Medical School, the US, Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, University Paris-Saclay, Suresnes, France, Dipartimento di Scienze Sanitarie Applicate e PsicoComportamentali, Universita` di Pavia, Italy, Centre for Biomedical Investigation Network on Respiratory Diseases (CibeRes), Barcelona, Spain, Royal College of Physicians of London, the UK, Graduate School of Medicine, Chiba University, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Allergic Rhinitis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Allergic Rhinitis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Prevalent cases of Allergic Rhinitis
• Diagnosed Prevalent Cases of Allergic Rhinitis
• Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis
• Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis
• Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis

Allergic Rhinitis Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Allergic Rhinitis Epidemiology Segmentation

Allergic Rhinitis Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Allergic Rhinitis? What will be the growth opportunities across the 7MM concerning the patient population of Allergic Rhinitis?
• What is the historical and forecasted Allergic Rhinitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the prevalent cases of Allergic Rhinitis in Japan higher than the US?
• Which country has a high patient share for Allergic Rhinitis?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Allergic Rhinitis prevalence cases in varying geographies over the coming years.
• A detailed overview of Age, Severity, and Allergen-specific diagnosed prevalence of Allergic Rhinitis.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Allergic Rhinitis Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Allergic Rhinitis cases in 2022?

The highest cases of Allergic Rhinitis was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Allergic Rhinitis cases in 2022?

The highest cases of Allergic Rhinitis were found in Japan among the 7MM in 2022.